Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
161
resultados
Última actualización
06/07/2025 [07:11:00]
Resultados 100 a 125 de 161
Resumen de: US2025164510A1
A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, and wherein concentration or levels of γ′ fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.
Resumen de: US2025161433A1
The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced “delayed type-I interferon”, resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.
Resumen de: US2025163107A1
Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.
Resumen de: US2025163026A1
The present invention is concerned with novel deuterium-enriched compounds of the general chemical structural formula I., and pharmaceutically acceptable salts, compositions, and methods of use thereof,wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25 are independently D (deuterium), H (hydrogen). The compounds of general chemical formula I are novel deuterium-enriched analogs of the SARS-CoV-2 main protease (MPro) inhibitor Nirmatrelvir for the treatment of COVID-19 and related diseases caused by various coronaviruses and their variants.
Resumen de: US2025161308A1
The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HGF/MET positive modulating agent.
Resumen de: US2025161262A1
Pharmaceutical compositions and methods for preventing, treating, relieving, or ameliorating symptoms of coronavirus infection, including COVID-19 and variants thereof, including treating or preventing severe illness from corona vims infection, comprising the administration of IMPDH inhibitors and/or restricted diets of guanosine-containing nucleosides or nucleotides.
Resumen de: US2025161431A1
This composition of this invention is comprised of live attenuated SARS-CoV-2 constructs as vaccines or research tools. Described herein is a highly attenuated SARS-CoV-2 with deleted accessory proteins and modified transcriptional regulator sequences (TRS) that can serve as a live-attenuated vaccine platform and a BSL-2 experimental system. Certain embodiments are directed to a live attenuated SARS-CoV-2 having a modified transcriptional regulatory sequence (TRS) and a deletion of one or more open reading frames selected from ORF3a, ORF3, ORF6, ORF7, and/or ORFS.
Resumen de: AU2023375894A1
The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Resumen de: WO2025106425A1
The disclosure provides a composition comprising a nucleic acid encoding a human alpha coronavirus (HCoV) receptor binding domain (RBD) peptide and a severe acute respiratory syndrome coronavirus 2 (SCoV2) RBD peptide.
Resumen de: WO2025106792A1
Provided herein is a stable mutant coronavirus spike protein stem domain in a prefusion conformation comprising: an S2 subunit only, that has been modified to comprise; at least one additional intra-monomeric disulfide bond that stabilizes the S2 subunit; and 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus pre-fusion, S2-only spike protein maintains the prefusion conformation. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, existing variants, or an emerging variant thereof.
Resumen de: WO2025106738A1
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.
Resumen de: PH12022552054A1
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Resumen de: KR20250071176A
본 발명은 사스-코로나바이러스-2 (SARS-CoV-2) 범용 항원 아미노산 서열로 이루어진 폴리펩타이드 및 상기 폴리펩타이드를 암호화하는 폴리뉴클레오타이드에 관한 것이며, 상기 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 SARS-CoV-2 감염증 예방용 백신 조성물 및 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명은 와일드 타입의 SARS-CoV-2 및 현존하는 SARS-CoV-2 변이주뿐만 아니라 가상의 SARS-CoV-2 변이주에까지 대응할 수 있는 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드의 특정 위치의 아미노산을 치환함으로써 구조 안정성을 더욱 향상시킨 SARS-CoV-2 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 백신 및 약학적 조성물을 제공한다.
Resumen de: EP4556004A1
The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses.The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.
Resumen de: EP4556021A1
The present disclosure provides a composition for inducing or maintaining an immune response against SARS-CoV-2 virus.
Resumen de: EP4556490A1
The present disclosure relates to a neutralizing antibody against SARS-coronavirus 2 (SARS-CoV2) or a variant virus thereof, or an antigen-binding fragment thereof. Since the neutralizing antibody of the present disclosure has inhibitory effect against SARS-coronavirus 2 and variants thereof (e.g., Delta variant, Omicron variant, etc.), it can be usefully used for prevention or treatment of infection by SARS-coronavirus 2 or variants thereof.
Resumen de: US12308098B1
A personal and reusable infection status passport device is disclosed that is configured to test for Covid-19 and infectious disease using photo and color analysis. The personal and reusable infection status passport device provides a supervisory testing unit/system to ensure testing is current and accurate. The quick and ease of use will allow for frequent testing so the individual will know their status without spending hours at a clinic or large sums of money on many single use tests. The test units are easier to produce and use with the main device. The device is capable of using a time stamp to ensure the test is current. The included processor and software will create a “status passport” system that will allow users to share their Covid-19 status as needed to comply with state, federal, local, and OSHA.
Resumen de: KR20250069453A
본 발명은 SARS-CoV-2 RBD 표적 HR2 펩타이드-융합 인간 항체의 활용 및 용도에 관한 것이다. 보다 구체적으로, 본 발명은 헵타드 반복 2 펩타이드(Heptad Repeat 2 Peptide, HR2) 및 코로나 바이러스의 수용체 결합 도메인과 특이적으로 결합하는 항체 또는 항원 결합 단편을 포함하는 단백질 복합체 및 이를 유효성분으로 포함하는, 코로나 바이러스 감염증의 치료용 약제학적 조성물에 관한 것이다. 본 발명의 상기 단백질 복합체는 잘 보존된 영역인 헵타드 반복 2 펩타이드를 코로나바이러스의 RBD 특이적 항체와 결합한 결과, 다양한 SARS-CoV-2 바이러스 변종에 대하여 독성없이 향상된 중화능을 나타내므로, 지속적으로 진화하는 SARS-CoV-2 변종에 효과적으로 대항할 수 있는 치료제 플랫폼으로써 유용하게 사용될 수 있다.
Resumen de: US2025152710A1
Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cells—called “Nukes” (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.
Resumen de: US2025152697A1
Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.
Resumen de: US2025152699A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Resumen de: WO2025098237A1
A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).
Resumen de: WO2025100882A1
The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.
Resumen de: AU2023353862A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.
Nº publicación: WO2025098545A1 15/05/2025
Solicitante:
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I [CZ]
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I
Resumen de: WO2025098545A1
The invention relates to small molecule inhibitors of formula (I) targeting the nsp14 protein of SARS- CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.
BOPI
Sede Electrónica
